Design of sustained-release matrix systems for a highly water-soluble compound, ABT-089

International Journal of Pharmaceutics

Volumn 157, Issue 1, 1997, Pages 43-52

  Qiu, Yihong ^a   Flood, Kolette ^a   Marsh, Kennan ^a   Carroll, Sherry ^a   Trivedi, Jay ^a   Arneric, Stephen P ^a   Krill, Steven L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Cholinergic channel modulator; Deconvolution; In vitro release; In vitro in vivo correlation; Matrix system; Sustained release

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; COTTON SEED OIL; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MACROGOL; METHYLCELLULOSE; POLYMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG FORMULATION; DRUG RELEASE; DRUG TRANSPORT; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TABLET MATRIX;

EID: 0030762831     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00215-9     Document Type: Article

References (18)

1. Arneric, S.P., Bannon, A.W., Briggs, C.A., Brioni, J.D., Buccafusco, J.J., Decker, M.W., Gopalakrishnan, M., Holladay, M.W., Kyncl, J., Lin, N.H., Marsh, K.G., Qiu, Y., Radek, R., Donnelly-Roberts, D.L., Sullivan, J.P., Williams, M., 1996. ABT-089: an orally active cholinergic channel modulator (ChCM) with cognitive enhancing and neuroprotective activity. In: Becker, R., Giacobini, E., Robert, P. (Eds.), Alzheimer's Disease: From Molecular Biology to Therapy. Birkhäuser, Boston.
2. Arneric, S.P., Campbell, J.E., Holladay, M.W., Johnson, P., Lin, N.H., Marsh, K.G., Petersen, B., Qiu, Y., Roberts, E.M., Rodrigues, A.D., Sullivan, J.P., Trivedi, J., Williams, M., submitted. ABT-089 [3-(2-(S)-pyrrolidinylmethoxy)-2-methyl-pyridine]: III. An orally effective cholinergic channel modulator with potential once-a-day dosing and cardiovascular safety. Drug Development Research, in press.
3. Cutler D. Linear system analysis in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics. 6:1978;265-282.
4. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research. 10:1993;1093-1095.
5. Desai S.J., Simonelli A.P., Higuchi W.I. Investigation of factors influencing release of solid drug dispersed in inert matrices. Journal of Pharmaceutical Sciences. 54:1965;1459-1464.
6. Foster T.P., Parrott E.L. Release of highly water-soluble medicinal compounds from inert, heterogeneous matrixes. I: Physical mixture. Journal of Pharmaceutical Sciences. 79:1990;806-810.
7. Gillespie W., Veng-Pedersen P. A polyexponential deconvolution method. Evaluation of the 'gastrointestinal bioavailability' and mean in vivo dissolution time of some ibuprofen dosage forms. Journal of Pharmacokinetics and Biopharmaceutics. 13:1985;289-307.
8. Higuchi T. Mechanism of sustained-action medication. Journal of Pharmaceutical Sciences. 52:1963;1145-1150.
9. Hildgen P., McMullen J.N. A new gradient matrix formulation and characterization. Journal of Controlled Release. 34:1995;263-271.
10. Hogan J.E. Hydroxypropylmethylcellulose sustained release technology. Drug Development and Industrial Pharmacy. 15:1989;975-999.
11. Hui Y., Marsh K.C. Sensitive detection of selected cholinergic channel activators derived with 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole. Journal of Pharmaceutical and Biomedical Analyses. 14:1995;131-142.
12. Lee, L., 1992. In: Kydonieus, A. (Ed.), Treatise on Controlled Drug Delivery: Diffusion-Controlled Matrix Systems. Marcel Dekker, New York, pp. 155-198.
13. Lin N.H., Gunn D.E., Ryther K.B., Garvey D.S., Donnelly-Roberts D.L., Decker M.W., Brioni J.D., Buckley M.J., Rodrigues A.D., Marsh K.G., Anerson D.J., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Structure-activity studies on ABT-089: an orally bioavailable 3-pyridyl ether cholinergic channel moderator with cognitive enhancing properties. Journal of Medicinal Chemistry. 40:1997;385-390.
14. Otsuka M., Matsuda Y. Controlled drug release of highly water-soluble pentoxifylline from time-limit disintegration-type wax matrix tablets. Pharmaceutical Research. 11:1994;351-354.
15. Otsuka M., Matsuda Y. Programmable drug release of highly water-soluble pentoxifylline from dry-coated wax matrix tablets. Journal of Pharmaceutical Sciences. 84:1995;443-447.
16. Scott D.C., Hollenbeck R.G. Design and manufacture of a zero-order sustained-release pellet dosage form through nonuniform drug distribution in a diffusional matrix. Pharmaceutical Research. 8:1991;156-161.
17. Skelly J.P.et al. In vitro and in vivo testing and correlation for oral controlled/modified-release dosage forms. Pharmaceutical Research. 7:1990;975-982.
18. Williams, M., Arneric, S.P., 1996. Alzheimer's disease: Prospects for treatment in the next decades. In: Brioni, J.D., Decker, M.W. (Eds.), Alzheimer's Disease. Wiley-Liss, New York, 1996.